通过将分子的结构特征纳入PROTAC降解器中,合理设计双降解器
Bowen Zhang1, Shan Gao1, Tingting Wu1
1Key Laboratory of Marine Drugs, Chinese Ministry of Educa-tion, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.
Journal of medicinal chemistry
|May 9, 2025
概括
研究人员发现了BWA-6047,一种针对AR/AR-V7和GSPT1蛋白的双降解剂. 这种新型的PROTAC和分子合物有效地减少了小鼠的瘤生长,显示出前列腺癌治疗的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 异常的蛋白质表达驱动各种疾病,需要新的治疗策略.
- 化向化体 (PROTAC) 和分子技术提供了降解致病蛋白质的创新方法.
研究的目的:
- 识别和描述针对雄激素受体 (AR),其变体AR-V7和GSPT1.1.的新型双重作用降解剂.
- 为潜在的癌症治疗发现具有PROTAC和分子功能强大的化合物.
主要方法:
- 结构-活性关系 (SAR) 研究是为了优化降解化合物而进行的.
- 在22Rv1细胞中进行了体外蛋白质降解试验,以评估化合物的效力.
- 使用LNCaP异种移植小鼠模型进行了体内疗效研究,以评估抗瘤活性和毒性.
主要成果:
- BWA-6047被确定为AR/AR-V7和GSPT1.1的强有力的双降解剂.
- 在22Rv1细胞中,BWA-6047表现出高降解效率 (AR:DC50 = 3.7nM,Dmax = 90%;AR-V7:DC50 = 3.0nM,Dmax = 93%;GSPT1:DC50 = 1.2nM,Dmax = 94%).在22Rv1细胞中,BWA-6047表现出高降解效率 (AR:DC50 = 3.7nM,Dmax = 90%;AR-V7:DC50 = 3.0nM,Dmax = 93%;GSPT1:DC50 = 1.2nM,Dmax = 94%).
- 口服BWA-6047显著抑制了小鼠LNCaP异种植的瘤生长,没有可观察到的毒性.
结论:
- 双重AR/AR-V7和GSPT1降解剂,以BWA-6047为例,代表了一个有前途的新型治疗剂类.
- BWA-6047表现出双重PROTAC和分子粘活性,为蛋白质降解提供了一种新的机制.
- 这些发现支持进一步调查BWA-6047和类似化合物用于晚期前列腺癌治疗.
相关概念视频
02:58Regulated Protein Degradation
7.1K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.1K
01:28Structure-Activity Relationships and Drug Design
474
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
474
02:18The Proteasome
8.4K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.4K